Andere talen Immuron Limited Nasdaq

Aandelen

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 23-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,313 ^USD	+0,55%		+0,55%	+23,34%

03/05	Immuron Limited kondigt aan dat Stephen Anastasiou ontslag heeft genomen als niet-uitvoerend bestuurder	CI
10/04	Wereldwijde omzet Immuron stijgt met 51% in maart; aandelen stijgen met 18%	MT

Immuron Limited to Present at the Emerging Growth Conference	07/05
Immuron Director Resignation	03/05
Immuron Director Resignation	03/05
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	03/05
Immuron to host Live Virtual Event	15/04
Immuron Travelan® sales continued strong growth	10/04
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	10/04
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	10/04
Sector Update: Health Care Stocks Gain Late Afternoon	07/03
Sector Update: Health Care	07/03
Top Midday Gainers	07/03
Top Premarket Gainers	07/03
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	07/03
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US	07/03
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	07/03
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Immuron Presentation Australian Biologics Festival 2024	21/02
Immuron Presentation Australian Biologics Festival 2024	21/02
Immuron achieves record Travelan® sales	13/02
Immuron achieves record Travelan® sales	13/02

Geen resultaten voor deze zoekopdracht